(Q34592340)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17176361%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

meta-analysis

0 references

title

Do selective COX-2 inhibitors increase the risk of cerebrovascular events? A meta-analysis of randomized controlled trials (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17176361%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17176361%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

Darren M. Ashcroft

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17176361%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

author name string

Chen LC

series ordinal

1

1 reference

3 August 2017

Ashcroft DM

series ordinal

2

1 reference

3 August 2017

1 December 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17176361%20AND%20SRC:MED&resulttype=core&format=json

Journal of Clinical Pharmacy and Therapeutics

23 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17176361%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17176361%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17176361%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

page(s)

565-576

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17176361%20AND%20SRC:MED&resulttype=core&format=json

Monitoring the safety of licensed medicines

23 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00774.X

Learning the value of drugs--is rofecoxib a regulatory success story?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00774.X

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00774.X

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00774.X

Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal anti-inflammatory medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00774.X

Understanding the NSAID related risk of vascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00774.X

Risk of cardiovascular events and rofecoxib: cumulative meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00774.X

Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00774.X

Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00774.X

Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00774.X

Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00774.X

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00774.X

What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00774.X

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00774.X

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00774.X

Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00774.X

Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00774.X

Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00774.X

Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00774.X

Efficacy of lumiracoxib in osteoarthritis: a review of nine studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00774.X

Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00774.X

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00774.X

Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00774.X

Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00774.X

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00774.X

NEJM stands by its criticism of Vioxx study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00774.X

The role of meta-analysis in the regulatory process for foods, drugs, and devices.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00774.X

Meta-analysis of individual patient data from randomized trials: a review of methods used in practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00774.X

Celecoxib and cardiovascular risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00774.X

Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00774.X

Celecoxib versus diclofenac in the management of osteoarthritis of the knee

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00774.X

Etoricoxib reduced pain and disability and improved quality of life in patients with chronic low back pain: a 3 month, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00774.X

A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00774.X

Risk factors for hospitalized gastrointestinal bleeding among older persons. Cardiovascular Health Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00774.X

A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00774.X

Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: a randomized, controlled comparison with placebo and naproxen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00774.X

Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00774.X